Diversifying scientific research: what the African Medicines Agency means for global health
By Blythe Sharman
The recent launch of the African Medicines Agency (AMA) could help Africa claim a more active role in global scientific research. The continent’s vast genetic diversity has hardly been studied and therefore is neglected in biomedical research; for example, only 4% of the data in the Pharmacogenomics Knowledgebase comes from individuals of African ancestry, and under 3% of clinical trials are conducted in Africa. This has meant that some people of African ancestry have experienced less effective or harmful responses to treatments and vaccines for diseases such as malaria and tuberculosis. Moreover, diseases that disproportionately affect African populations, like sickle-cell disease, often receive less attention in research than those more common in European populations. By working closely with Africa-based research institutions, the AMA could help to increase numbers of clinical trials conducted on the continent, allowing Africa to play a more pivotal role in shaping global health.
The AMA could incentivise the use of in vitro models that use cells with African genomes, helping to ensure that drug discovery and testing better reflect the genetic diversity of the continent
Increasingly, many drug tests are relying on in vitro models made from human cells, which can be manipulated to mimic the structure and function of specific organs and tissues. However, most of these cell samples have come from individuals of European ancestry, once again excluding African genomes from clinic trials. The AMA could incentivise the use of in vitro models that use cells with African genomes, helping to ensure that drug discovery and testing better reflect the genetic diversity of the continent. This would help produce safer and more effective treatments for people of African ancestry, as well as improving understanding of drug response to genetic variation.
Conducting clinical trials in Africa remains a challenge due to limited laboratories, lack of experts in research, and inconsistent cross-country regulation, which have led to a higher prevalence of poor-quality medicines and reduced access to new treatments. For example, delays in the approval for treatments of HIV, malaria, and tuberculosis — already approved by regulators such as the European Medicines Agency and the U.S. Food and Drug Administration — meant these treatments were not used across Africa for many years. By harmonising regulatory standards and facilitating biomedical training, the AMA can strengthen the continent’s research capacity and accelerate access to treatments.
It’s extremely important that African pharmacogenomic data are integrated into biomedical research. Ensuring that preclinical models reflect African genomes will help to improve the health of people with African ancestry, and help to find links between genetic variation, diseases, and treatments. Through this, the AMA can help make drug discovery and testing more inclusive and ensure that future treatments are safer and more effective for African populations.
Image: satheeshsankaran via Pixabay

